View the Whatcom County Respiratory Virus Dashboard Here
Summary Background On Oct. 23, 2023, Centers for Disease Control and Prevention (CDC) issued a health alert about the limited supply of nirsevimab. CDC recommended healthcare providers prioritize nirsevimab for infants born later in RSV (respiratory syncytial virus) season or for those at increased risk for severe illness. On Jan. 5, 2024, CDC issued updated guidance about the increased … 02/09/24 Health Advisory: RSV Prevention Updates
An active measles outbreak investigation is underway in Clark and Wahkiakum Counties. As of Jan. 10, 2024, investigators have identified 3 lab-confirmed and 3 epidemiologically linked measles cases in unvaccinated adults. Symptoms began in mid-to-late December. All report isolating at home during their contagious period. Investigators have not identified any public exposure locations. Healthcare providers … 01/19/24 Health Advisory: Measles Outbreak in Southwest Washington
A large outbreak of tuberculosis (TB) in the state prison system may affect more than 800 people who were incarcerated. Requested actions Ask patients about risk factors for TB exposure: Test people with risk factors unless they have a known history of TB infection or TB disease. Evaluate people who test positive to rule out … 12/13/23 Health Advisory: Test for tuberculosis people who were incarcerated
Action requested Centers for Disease Control and Prevention (CDC) recommends you test children born to people with: Test children for HCV RNA at 2–6 months old, up to 17 months old. Give untested children older than 18 months an HCV antibody test with reflex to HCV RNA. Report hepatitis C cases in pregnant people and the … 12/06/23 Health Advisory: Test perinatally exposed children for hepatitis C.
The new adjuvanted (2023–2204) formulation of Novavax COVID-19 vaccine is authorized for people 12 years or older as follows: Updated 2023–2024 COVID-19 vaccine availability may be limited and vary by location. Help patients understand this situation and thank them for their patience. Resources Questions?
This 2023–2024 respiratory illness season, we’re monitoring 3 common causes of respiratory illness that circulate in Whatcom County: influenza, respiratory syncytial virus (RSV), and COVID-19. Influenza Centers for Disease Control and Prevention (CDC) estimates that in the United States last flu season (2022–2023) caused: Those at highest risk for severe illness include: Guidelines RSV RSV … 09/28/23 Health Advisory: 2023–2024 Respiratory Illness Season
FDA deauthorized previous bivalent COVID-19 vaccines. On Sept. 11, 2023, FDA deauthorized previous bivalent COVID-19 vaccines from Moderna and Pfizer. CDC recommends new, updated (2023–2024) COVID-19 vaccines. CDC’s new, updated (2023–2014) COVID-19 vaccine recommendations: Vaccination remains the best way to prevent COVID-19 hospitalization and death and reduces the risk of long COVID. The new, updated … 09/21/23 Health Advisory: New COVID-19 Vaccines Authorized, Previous Bivalent COVID-19 Vaccines Deauthorized
Penicillin G benzathine (Bicillin L-A) is in short supply due to increased demand. Syphilis is increasing in all groups, especially in heterosexual people. Reserve Bicillin L-A for pregnant people with or exposed to syphilis, or babies with congenital syphilis. Read on for syphilis: Treatment. Testing with reverse algorithm. Reserve Bicillin L-A for pregnant people. Reserve … 07/06/23 Health Advisory: Syphilis Treatment Impacted by Bicillin L-A Shortage
Actions requested Background Washington State Department of Health (DOH) and Centers for Disease Control and Prevention (CDC) are investigating a cluster of antibiotic-resistant infections that may be linked to artificial tears. The most frequently reported brand was EzriCare Artificial Tears, a preservative-free product dispensed in muti-dose bottles. These over-the-counter eye drops are sold widely in … 02/03/23 Health Advisory: Multistate Cluster of Antibiotic Resistant Bacteria Associated with Artificial Tears
Bebtelovimab no longer authorized in the United States. On Nov. 30, 2022, U.S. Food and Drug Administration (FDA) revoked its Emergency Use Authorization (EUA) for bebtelovimab. Bebtelovimab is a monoclonal antibody used to treat COVID-19. FDA revoked the EUA because the drug lost efficacy against most SARS-CoV-2 variants currently circulating in the United States. Currently, … 12/12/22 Health Advisory: COVID-19 Therapeutics Updates
